Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Neoadjuvant Monotherapy in Resectable Acral and Mucosal Melanoma (Phase II, Single-Arm)
ChiCTR2500112379Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in acral lentiginous melanoma (ALM) and mucosal melanoma (MM), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Major pathological response rate. Started Nov 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
acral lentiginous melanoma (ALM)mucosal melanoma (MM)
Beyond the preview
Go deeper on ChiCTR2500112379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112379.